ABSTRACT
Objectives To assess the influence of corticosteroid pulses on 60-days mortality in hospitalized patients with severe COVID-19, intensive care admission, and hospital stay.
Methods We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865.096 people). We selected patients with confirmed COVID-19 and lung involvement with a pO2/FiO2 < 300, excluding those exposed to immunosuppressors before or during hospitalization, patients terminally ill at admission, or died the first 24 hours. We performed a propensity score matching (PSM) adjusting covariates that modify the probability of being treated. Then we used a Cox regression model in the PSM group to consider factors affecting mortality.
Results From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses, and 133 were not. 30,3% (37/122) of patients died in the corticosteroid pulses group and 42,9% (57/133) in the non-exposed cohort. These differences (12,6%) were statically significant (log-rank 4.72, p=0,03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log-rank 5.31, p=0,021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0,561, p= 0,039). There were no significant differences in intensive care admission rate (p=0,173). The hospital stay was longer in the corticosteroid group (p<0,001).
Conclusions This study provides evidence about treatment with corticosteroid pulses in severe COVID-19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both exposed and non-exposed groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There are no funds supporting our study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Local ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email (in order of appearance): icusac{at}hotmail.com, alvaro_aparisi{at}hotmail.com, mmarcos{at}usal.es; mcdeybarrafalcon{at}gmail.com, ciglesias018{at}gmail.com, veloccs{at}yahoo.es, juliocbarraza{at}icloud.com, carlos.duenas{at}hotmail.com, santiagojuarros{at}separ.es, berodriguezal{at}saludcastillayleon.es, jmoterino{at}saludcastillayleon.es, mmonterob{at}saludcastillayleon.es, lmoralejo{at}yahoo.es, dandaluz{at}saludcastillayleon.es, roberlaguna{at}hotmail.com
Conflicts of interest: None.
Financial sources: None
Data Availability
We can provide all data in the study if requested with a funded reason.
ABBREVIATIONS
- ARDS
- Acute respiratory distress syndrome
- COVID-19
- Coronavirus disease 2019
- ICU
- Intensive care unit
- PSM
- Propensity score matching
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- PCR
- Polymerase chain reaction
- IFN—γ
- Interferon-γ
- TNF- α
- Tumor necrosis factor α
- LDH
- Lactate dehydrogenase
- CRP
- C-reactive protein
